Hikma Pharmaceuticals PLC (LON:HIK) has raised its interim dividend after a solid first-half performance, with the drugs firm experiencing higher demand for injectables due to the coronavirus pandemic.
The FTSE 100-listed group said the injectables segment is expected to deliver revenue of US$950mln-980mln for the full year as that momentum is forecast to continue.
READ: Hikma Pharma upgraded to ‘overweight’ from ‘equal-weight’ by Morgan Stanley in note highlighting “hidden operating leverage”
Hikma said revenue in its generics business is estimated to be US$720mln-760mln, including US$20mln-40mln forecast for the launch of generic Advair Diskus, an asthma treatment.
The pharma group declared a dividend of US$0.16 per share, for the six months to June 30, 2020, up 14% on last year.
Revenue in the period advanced 8% to US$1.1bn, while profit before tax was up 18% to US$274mln. Cash and cash equivalents at period-end were US$413mln.